Early-stage oncology Target a biopharma or diagnostics partner focused on precision oncology, offering Nemucore's RNA-based companion diagnostic paired with NMI-900 to improve patient selection and potentially expand the addressable AML market before larger competitors.

High-growth potential Position Nemucore as a biotech with a clear path to regulatory approval within five years, highlighting the opportunity for collaborators to co-develop or license the drug-diagnostic platform ahead of the competition.

Limited current scale Leverage the small team size to propose agile collaboration models, such as sponsored research, joint development agreements, or milestone-based licensing with major pharma players seeking external innovation.

Data and tooling Offer access to a unique RNA-based diagnostic approach as a differentiator in partner ecosystems, suggesting integration with existing clinical trial data platforms and payer-ready economic models.

Strategic fit Target large oncology and hematology players with established regulatory and commercialization capabilities who could accelerate Phase I–III timelines through collaboration or acquisition discussions.